

# John H Alexander

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3086825/publications.pdf>

Version: 2024-02-01

306  
papers

28,660  
citations

7096

78  
h-index

5679

162  
g-index

311  
all docs

311  
docs citations

311  
times ranked

23126  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	3.8	18
2	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
3	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
4	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	2.8	12
5	Rationale and design of a randomized trial evaluating an external support device for saphenous vein coronary grafts. <i>American Heart Journal</i> , 2022, 246, 12-20.	2.7	1
6	Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. <i>Open Heart</i> , 2022, 9, e001892.	2.3	0
7	Equipoise in Clinical Trials: Enough Uncertainty in Whose Opinion?. <i>Circulation</i> , 2022, 145, 943-945.	1.6	3
8	Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. <i>American Heart Journal</i> , 2022, 249, 86-97.	2.7	8
9	Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2022, 248, 35-41.	2.7	0
10	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	2.7	6
11	Prophylactic levosimendan in patients with low ejection fraction undergoing coronary artery bypass grafting: A pooled analysis of two multicentre randomised controlled trials. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2022, 41, 101107.	1.4	11
12	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. <i>JAMA Cardiology</i> , 2022, 7, 682.	6.1	3
13	External Support for Saphenous Vein Grafts in Coronary Artery Bypass Surgery. <i>JAMA Cardiology</i> , 2022, 7, 808.	6.1	10
14	Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	1.4	17
15	Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). <i>American Journal of Cardiology</i> , 2022, 178, 11-17.	1.6	3
16	Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1504-1511.	0.8	7
17	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2021, 231, 18-24.	2.7	12
18	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	2.7	60

#	ARTICLE	IF	CITATIONS
19	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.7	11
20	Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 713-724.	2.8	21
21	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 713-720.	2.9	8
22	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 254.	7.4	299
23	Preventing Atrial Fibrillation After Cardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2021, 77, 68-70.	2.8	7
24	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 226-236.	2.9	6
25	Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention—Reply. <i>JAMA Cardiology</i> , 2021, 6, 241.	6.1	0
26	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	2.3	7
27	The association between coronary graft patency and clinical status in patients with coronary artery disease. <i>European Heart Journal</i> , 2021, 42, 1433-1441.	2.2	32
28	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 1215-1223.	1.6	9
29	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009614.	4.8	1
30	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2021, 397, 2253-2263.	13.7	366
31	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	5.9	5
32	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	3.8	17
33	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOroNavirus)â€“Coalition IV trial. <i>American Heart Journal</i> , 2021, 238, 1-11.	2.7	19
34	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
35	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	2.8	58
36	Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data. <i>European Heart Journal</i> , 2021, 43, 18-28.	2.2	59

#	ARTICLE	IF	CITATIONS
37	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 – Authors' reply. <i>Lancet</i> , The, 2021, 398, 1304.	13.7	0
38	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	7.4	186
39	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e023143.	3.7	0
40	Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2230-2240.e15.	0.8	7
41	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.8	40
42	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E102-E109.	1.7	10
43	Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	1.8	4
44	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2020, 221, 1-8.	2.7	19
45	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
46	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. <i>Diabetology International</i> , 2020, 11, 129-141.	1.4	17
47	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2020, 302, 53-58.	1.7	5
48	Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy – Reply. <i>JAMA Cardiology</i> , 2020, 5, 111.	6.1	1
49	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020, 141, 10-20.	1.6	24
50	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines – Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e017024.	3.7	23
51	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. <i>New England Journal of Medicine</i> , 2020, 383, 2117-2126.	27.0	161
52	Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. <i>American Heart Journal</i> , 2020, 228, 91-97.	2.7	6
53	Sex-related differences in outcomes after coronary artery bypass surgery – A patient-level pooled analysis of randomized controlled trials: rationale and study protocol. <i>Journal of Cardiac Surgery</i> , 2020, 35, 2754-2758.	0.7	4
54	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	2.8	50

#	ARTICLE	IF	CITATIONS
55	Risk for non-home discharge following surgery for ischemic mitral valve disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 162, 1769-1778.e7.	0.8	6
56	Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e017155.	3.7	6
57	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	5.9	5
58	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	3.7	37
59	Are We At Risk of Depriving Patients Lifesaving Cardiac Surgery?. <i>Circulation</i> , 2020, 142, 1797-1798.	1.6	2
60	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020, 226, 49-59.	2.7	118
61	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 128-129.	2.8	0
62	Serial measurement of interleukinâ€“6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and REâ€“LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	3.8	14
63	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	2.8	28
64	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
65	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
66	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	2.8	50
67	Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. <i>American Heart Journal</i> , 2020, 227, 91-99.	2.7	60
68	Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 787.	7.4	7
69	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	6.1	71
70	Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. <i>Journal of Internal Medicine</i> , 2020, 288, 248-259.	6.0	3
71	Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. <i>American Heart Journal</i> , 2020, 223, 84-86.	2.7	0
72	Association Between Delays in Mechanical Ventilation Initiation and Mortality in Patients With Refractory Cardiogenic Shock. <i>JAMA Cardiology</i> , 2020, 5, 965.	6.1	18

#	ARTICLE	IF	CITATIONS
73	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	8.6	44
74	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019, 215, 106-113.	2.7	7
75	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
76	Safe and Effective Anticoagulation: What Does Drug Concentration Add?. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1772-1773.	2.6	2
77	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.6	18
78	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
79	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. <i>Circulation</i> , 2019, 140, 1960-1963.	1.6	7
80	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	2.7	7
81	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	6.1	198
82	Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. <i>European Journal of Internal Medicine</i> , 2019, 65, 4-5.	2.2	4
83	Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2427-2435.	2.8	33
84	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 27-34.	2.1	11
85	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	27.0	833
86	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019, 42, 568-571.	1.8	80
87	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 345-352.	2.1	13
88	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
89	Anticoagulation-Related Major Bleeding in Patients With Atrial Fibrillation. <i>Circulation</i> , 2019, 140, 1802-1804.	1.6	2
90	Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. <i>European Heart Journal</i> , 2019, 40, 3768-3770.	2.2	11

#	ARTICLE	IF	CITATIONS
91	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart, 2019, 105, 235-242.	2.9	19
92	Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial). American Journal of Cardiology, 2019, 123, 571-575.	1.6	8
93	Longitudinal Changes in Regional Cerebral Perfusion and Cognition After Cardiac Operation. Annals of Thoracic Surgery, 2019, 107, 112-118.	1.3	9
94	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
95	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation, 2019, 139, 351-361.	1.6	126
96	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA - Journal of the American Medical Association, 2019, 321, 69.	7.4	830
97	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. American Heart Journal, 2019, 208, 123-131.	2.7	54
98	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. American Heart Journal, 2019, 208, 81-90.	2.7	25
99	Antithrombotic Therapy Following CABG. Journal of the American College of Cardiology, 2019, 73, 131-133.	2.8	2
100	Digoxin and Mortality in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 1063-1074.	2.8	147
101	Ticagrelor Following Coronary Artery Bypass Grafting. JAMA - Journal of the American Medical Association, 2018, 319, 1661.	7.4	5
102	Stroke prevention in atrial fibrillation: re-defining "real-world data" within the broader data universe. European Heart Journal, 2018, 39, 2932-2941.	2.2	22
103	The Clinical Trials Transformation Initiative: Looking back, looking forward. Clinical Trials, 2018, 15, 3-4.	1.6	6
104	Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. American Heart Journal, 2018, 199, 150-155.	2.7	2
105	Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. American Heart Journal, 2018, 200, 96-101.	2.7	117
106	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 234.	6.1	46
107	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other) Trial. JAMA Cardiology, 2018, 3, 234.	3.7	51
108	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 75-81.	3.0	9

#	ARTICLE	IF	CITATIONS
109	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, T) ETQq1 1 0.784314 rgBT /Ovgrlock 10 T	2.2	92
110	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart, 2018, 104, 1292-1299.	2.9	14
111	Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. American Heart Journal, 2018, 198, 129-134.	2.7	4
112	Rationale, design, and baseline characteristics of the CARdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂ®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovascular Diabetology, 2018, 17, 39.	6.8	70
113	An open-Label, 2 Ã— 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal. 2018. 200. 17-23.	2.7	69
114	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. Journal of Thrombosis and Thrombolysis, 2018, 45, 469-476.	2.1	11
115	Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2018, 319, 1331.	7.4	100
116	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. American Heart Journal, 2018, 197, 1-8.	2.7	6
117	Taskâ€related changes in degree centrality and local coherence of the posterior cingulate cortex after major cardiac surgery in older adults. Human Brain Mapping, 2018, 39, 985-1003.	3.6	22
118	Secondary surgical-site infection after coronary artery bypass grafting: A multi-institutional prospective cohort study. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1555-1562.e1.	0.8	26
119	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. American Heart Journal, 2018, 197, 133-141.	2.7	17
120	Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. American Journal of Medicine, 2018, 131, 269-275.e2.	1.5	87
121	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart, 2018, 5, e000908.	2.3	12
122	Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 1113.	6.1	27
123	Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal, 2018, 203, 39-48.	2.7	19
124	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 721-733.	2.8	31
125	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. American Heart Journal, 2018, 201, 25-32.	2.7	9
126	Crowdsourcing consensus: proposal of a novel method for assessing accuracy in echocardiography interpretation. International Journal of Cardiovascular Imaging, 2018, 34, 1725-1730.	1.5	1



#	ARTICLE	IF	CITATIONS
127	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
128	Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, .	2.2	10
129	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	34
130	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017, 185, 140-149.	2.7	54
131	Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. <i>Annals of Thoracic Surgery</i> , 2017, 104, 98-105.	1.3	7
132	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 324.	6.1	28
133	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 623-628.	2.9	54
134	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017, 130, 1170-1176.	1.5	8
135	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€ Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1661-1670.	5.6	59
136	Dabigatran Compared With Rivaroxaban vs Warfarin. <i>JAMA Internal Medicine</i> , 2017, 177, 742.	5.1	1
137	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	2.6	3
138	Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
139	Pneumonia after cardiac surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1384-1391.e3.	0.8	79
140	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	6.1	18
141	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017, 129, 2980-2987.	1.4	85
142	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	2.7	26
143	Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 446-453.	2.1	5
144	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017, 376, 2032-2042.	27.0	225

#	ARTICLE	IF	CITATIONS
145	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273.	2.0	20
146	Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trialâ€”rationale and study protocolâ€”. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 1031-1040.	1.4	136
147	Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2017, 130, 1440-1448.e1.	1.5	120
148	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	20
149	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2017, 227, 443-449.	1.7	3
150	Restingâ€”State Functional Connectivity and Cognition After Major Cardiac Surgery in Older Adults without Preoperative Cognitive Impairment: Preliminary Findings. <i>Journal of the American Geriatrics Society</i> , 2017, 65, e6-e12.	2.6	63
151	Nonsteroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. <i>American Journal of Medicine</i> , 2017, 130, 462-468.	1.5	19
152	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1918-1930.	1.6	148
153	Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2016, 374, 1954-1964.	27.0	170
154	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	13.7	389
155	The â€”obesity paradoxâ€”™ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Tj ETQq1 1 0.784314 rg 2869-2878.	2.2	194
156	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Nonâ€”ST-Segmentâ€”Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573.	1.6	17
157	Using Data to Guide Anticoagulation in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 121.	6.1	1
158	Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2016, 375, e22.	27.0	33
159	Relation of Postâ€”Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves With Long-Term Cardiovascular Death in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016, 118, 1655-1660.	1.6	3
160	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
161	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2016, 180, 22-28.	2.7	25
162	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to peginvacogin, a PEGylated aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1712-1715.	2.9	156

#	ARTICLE	IF	CITATIONS
163	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	2.7	23
164	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. <i>JAMA Cardiology</i> , 2016, 1, 673.	6.1	81
165	Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty. <i>Circulation</i> , 2016, 134, 1247-1256.	1.6	58
166	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ, The</i> , 2016, 353, i2868.	6.0	123
167	REGULATE-PCI trial – Author's reply. <i>Lancet, The</i> , 2016, 387, 1510-1511.	13.7	0
168	Response to Letters Regarding Article, “Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial”. <i>Circulation</i> , 2016, 133, e665.	1.6	1
169	Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1610-1613.e7.	2.9	215
170	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. <i>JAMA Cardiology</i> , 2016, 1, 451.	6.1	137
171	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes. <i>Circulation</i> , 2016, 133, 131-138.	1.6	70
172	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
173	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517.	2.9	67
174	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	2.7	16
175	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016, 174, 60-67.	2.7	4
176	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.2	329
177	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016, 387, 349-356.	13.7	109
178	Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 682-689.	1.4	11
179	Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2016, 31, 106-14.	0.6	3
180	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	3.0	59

#	ARTICLE	IF	CITATIONS
181	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	68
182	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, ehv447.	2.2	35
183	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". <i>Circulation</i> , 2015, 132, e29.	1.6	3
184	Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002171.	3.7	89
185	Costs Associated With Health-Care-Associated Infections in Cardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2015, 65, 15-23.	2.8	62
186	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the Apixaban for Prevention of Acute Ischemic Events 2 trial. <i>American Heart Journal</i> , 2015, 169, 531-538.	2.7	9
187	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	3.2	37
188	Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. <i>European Heart Journal</i> , 2015, 36, 2733-2741.	2.2	52
189	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	2.7	15
190	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015, 101, 1475-1484.	2.9	13
191	Response to Letter Regarding Article, "Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation: A 20-year Experience". <i>Circulation</i> , 2015, 131, e378-9.	1.6	1
192	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2015, 132, 624-632.	1.6	203
193	Outcomes After Nonemergent Electrical Cardioversion for Atrial Arrhythmias. <i>American Journal of Cardiology</i> , 2015, 115, 1407-1414.	1.6	7
194	Predictors of Long-term Clinical Endpoints in Patients With Refractory Angina. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	61
195	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 357-367.	2.2	30
196	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 777-787.	2.8	39
197	The Preservation and Handling of Vein Grafts in Current Surgical Practice. <i>JAMA Surgery</i> , 2015, 150, 681.	4.3	12
198	Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery. <i>BMJ Open</i> , 2015, 5, e006920-e006920.	1.9	13

#	ARTICLE	IF	CITATIONS
199	Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2015, 4, e001512.	3.7	19
200	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015, 169, 25-30.	2.7	61
201	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	2.7	23
202	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	2.2	144
203	Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE. <i>Circulation</i> , 2015, 132, .	1.6	12
204	Abstract 17205: Polypharmacy and the Impact of Apixaban on Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. <i>Circulation</i> , 2015, 132, .	1.6	0
205	Abstract 12404: Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function over Time: Insights From the ARISTOTLE Trial. <i>Circulation</i> , 2015, 132, .	1.6	0
206	Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. <i>Circulation</i> , 2015, 132, .	1.6	0
207	Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". <i>Circulation</i> , 2014, 129, e21-2.	1.6	1
208	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. <i>JAMA Surgery</i> , 2014, 149, 798.	4.3	74
209	Standardizing definitions for hybrid coronary revascularization. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 556-560.	0.8	36
210	Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 331-337.	2.1	4
211	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	2.8	308
212	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 625-634.	1.6	110
213	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.	2.8	133
214	Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1082-1087.	2.8	228
215	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1847-1858.	1.6	243
216	Reply. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1890.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Surgical Treatment of Moderate Ischemic Mitral Regurgitation. <i>New England Journal of Medicine</i> , 2014, 371, 2178-2188.	27.0	358
218	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 224-232.	2.2	140
219	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2014, 130, 1445-1451.	1.6	181
220	Readmissions After Cardiac Surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1274-1280.	1.3	98
221	Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus. <i>American Heart Journal</i> , 2014, 168, 471-478.	2.7	22
222	Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes After Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2014, 97, 824-830.	1.3	13
223	Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation. <i>Circulation</i> , 2014, 129, 2547-2556.	1.6	84
224	Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014, 168, 303-309.	2.7	128
225	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014, 124, 3692-3698.	1.4	149
226	Endoscopic Harvesting Device Type and Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. <i>Annals of Surgery</i> , 2014, 260, 402-408.	4.2	15
227	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. <i>EuroIntervention</i> , 2014, 10, 431-438.	3.2	26
228	Abstract 16741: The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group. <i>Circulation</i> , 2014, 130, .	1.6	2
229	Abstract 15473: The Use of Coronary Artery Bypass Grafts in Non-significant Lesions: Is There Harm to Patients?. <i>Circulation</i> , 2014, 130, .	1.6	0
230	Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 384-393.	2.1	14
231	Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2013, 170, 215-220.	1.7	55
232	Effect of Levosimendan on Survival and Adverse Events After Cardiac Surgery: A Meta-Analysis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 1224-1232.	1.3	100
233	Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 451-460.	3.9	136
234	Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2013, 166, 549-558.	2.7	42

#	ARTICLE	IF	CITATIONS
235	Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial. <i>American Heart Journal</i> , 2013, 166, 559-565.e1.	2.7	9
236	Saphenous vein graft failure and clinical outcomes: Toward a surrogate end point in patients following coronary artery bypass surgery?. <i>American Heart Journal</i> , 2013, 165, 639-643.	2.7	43
237	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
238	The safety and efficacy of apixaban: where do we stand in 2013?. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 559-567.	2.4	3
239	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013, 34, 2464-2471.	2.2	154
240	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. <i>European Heart Journal</i> , 2013, 34, 2481-2489.	2.2	85
241	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1670-1680.	2.2	175
242	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. <i>Annals of Surgery</i> , 2013, 257, 824-833.	4.2	292
243	Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2012, 125, 749-756.	1.6	143
244	Association Between Endoscopic vs Open Vein-Graft Harvesting and Mortality, Wound Complications, and Cardiovascular Events in Patients Undergoing CABG Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 475-84.	7.4	86
245	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1749-1758.	13.7	175
246	Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2012, 33, 2821-2830.	2.2	491
247	Authors' reply to "The not so "ideal"™ body weight" based dosing of Integrilin in obesity". <i>American Heart Journal</i> , 2012, 163, e25.	2.7	1
248	Edifoligide and long-term outcomes after coronary artery bypass grafting: PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. <i>American Heart Journal</i> , 2012, 164, 379-386.e1.	2.7	43
249	Novel Oral Anticoagulants After Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 265-271.	2.6	1
250	Comparison of Incidence of Bleeding and Mortality of Men Versus Women With ST-Elevation Myocardial Infarction Treated With Fibrinolysis. <i>American Journal of Cardiology</i> , 2012, 109, 320-326.	1.6	24
251	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurology</i> , The, 2012, 11, 503-511.	10.2	252
252	Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: A report from the Cardiothoracic Surgical Trials Network. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 111-117.e1.	0.8	29

#	ARTICLE	IF	CITATIONS
253	Promise of Factor Xa Inhibition in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2012, 14, 70-78.	2.9	3
254	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	27.0	918
255	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. <i>American Heart Journal</i> , 2011, 161, 261-268.e2.	2.7	36
256	The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. <i>American Heart Journal</i> , 2011, 162, 996-1002.	2.7	4
257	Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. <i>American Journal of Medicine</i> , 2011, 124, 48-57.	1.5	31
258	Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. <i>European Heart Journal</i> , 2011, 32, 2412-2419.	2.2	41
259	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	27.0	7,537
260	Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction*. <i>Critical Care Medicine</i> , 2011, 39, 78-83.	0.9	78
261	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 242-266.	2.1	2
262	Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 585.	7.4	236
263	Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery. <i>Circulation</i> , 2011, 124, 280-288.	1.6	116
264	Thrombomodulin Gene Variants Are Associated With Increased Mortality After Coronary Artery Bypass Surgery in Replicated Analyses. <i>Circulation</i> , 2011, 124, S143-8.	1.6	32
265	Apixaban for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Primary Results of the ARISTOTLE Trial. <i>Journal of Arrhythmia</i> , 2011, 27, SY06_5.	1.2	0
266	Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 104, 976-983.	3.4	55
267	First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2010, 122, 614-622.	1.6	91
268	Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. <i>American Heart Journal</i> , 2010, 159, 331-339.	2.7	407
269	Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. <i>Circulation</i> , 2009, 119, 2877-2885.	1.6	428
270	Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery. <i>New England Journal of Medicine</i> , 2009, 361, 235-244.	27.0	356



#	ARTICLE	IF	CITATIONS
271	Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. American Heart Journal, 2009, 158, 792-798.	2.7	40
272	The current state of antiplatelet therapy in acute coronary syndromes: The data and the real world. Cleveland Clinic Journal of Medicine, 2009, 76, S16-S23.	1.3	10
273	Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis, 2008, 26, 167-174.	2.1	14
274	Impact of Perioperative Myocardial Infarction on Angiographic and Clinical Outcomes Following Coronary Artery Bypass Grafting (from PProject of Ex-vivo Vein graft ENgineering via Transfection) Tj ETQq0 0 0 rgBT, Overlock 10 Tf 50 6	1.6	10
275	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) IIâ€”study design and rationale. American Heart Journal, 2008, 155, 600-608.	2.7	6
276	Clopidogrel Treatment and the MEND-CABG II Trialâ€”Reply. JAMA - Journal of the American Medical Association, 2008, 300, 1021.	7.4	0
277	Efficacy and Safety of Pyridoxal 5â€²-Phosphate (MC-1) in High-Risk Patients Undergoing Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2008, 299, 1777.	7.4	42
278	Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease. Circulation, 2008, 117, 2865-2874.	1.6	125
279	Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. European Heart Journal, 2007, 28, 425-432.	2.2	19
280	Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2007, 297, 1657.	7.4	327
281	Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shockâ€”Reply. JAMA - Journal of the American Medical Association, 2007, 298, 969.	7.4	0
282	Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery. Annals of Thoracic Surgery, 2007, 83, 993-1001.	1.3	86
283	Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials. American Heart Journal, 2006, 151, 16-24.	2.7	26
284	First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology. Circulation, 2006, 114, 2490-2497.	1.6	202
285	Efficacy and Safety of Edifoligideâ€”Reply. JAMA - Journal of the American Medical Association, 2006, 295, 1513.	7.4	1
286	Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction. Circulation Research, 2006, 99, 1141-1147.	4.5	47
287	Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2005, 294, 2446.	7.4	557
288	Association of Height With Outcomes in Patients With Acute Myocardial Infarction Receiving Reperfusion Therapy. American Journal of Cardiology, 2005, 95, 1371-1375.	1.6	1

#	ARTICLE	IF	CITATIONS
289	Relation of Early Saphenous Vein Graft Failure to Outcomes Following Coronary Artery Bypass Surgery. American Journal of Cardiology, 2005, 96, 1254-1259.	1.6	113
290	Relationship of Incorrect Dosing of Fibrinolytic Therapy and Clinical Outcomes. JAMA - Journal of the American Medical Association, 2005, 293, 1746.	7.4	21
291	Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. American Heart Journal, 2005, 149, 670-674.	2.7	94
292	The PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial. American Heart Journal, 2005, 150, 643-649.	2.7	48
293	Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic) Tj ETQq1 1 0.7843d 4 rgBT 20verloc	2.7	48
294	Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 2153-2159.	2.8	55
295	Feasibility of point-of-care echocardiography by internal medicine house staff. American Heart Journal, 2004, 147, 476-481.	2.7	136
296	Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. American Heart Journal, 2004, 147, 993-998.	2.7	38
297	Integrating antithrombin and antiplatelet therapies with early invasive management for nonâ€“ST-segment elevation acute coronary syndromes. American Journal of Medicine, 2004, 116, 119-129.	1.5	4
298	Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. American Heart Journal, 2003, 145, 636-642.	2.7	29
299	Platelets and Thrombolysis: Cooperation or Contrariety?. Cardiology, 2001, 1, 281-290.	0.3	5
300	Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. American Journal of Cardiology, 2001, 88, 1240-1245.	1.6	20
301	Placebo-Controls in Short-Term Clinical Trials of Hypertension. Science, 2001, 292, 2013-2015.	12.6	38
302	Association Between Minor Elevations of Creatine Kinase-MB Level and Mortality in Patients With Acute Coronary Syndromes Without ST-Segment Elevation. JAMA - Journal of the American Medical Association, 2000, 283, 347.	7.4	95
303	Highlights from the American Heart Association 72nd scientific sessions: November 6 to 10, 1999. American Heart Journal, 2000, 139, 359-370.	2.7	10
304	The clinical use of an esophageal Doppler monitor for hemodynamic monitoring in sepsis. Journal of Clinical Monitoring and Computing, 1999, 15, 223-225.	1.6	13
305	Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal, 1999, 137, 792-798.	2.7	106
306	Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials. American Heart Journal, 1999, 137, 799-805.	2.7	57